培养扩增间充质基质细胞治疗4种炎症性关节炎的有效性与安全性:36项随机对照试验的系统评价与Meta分析
该系统评价与Meta分析纳入36项随机对照试验共2076例参与者,涵盖类风湿关节炎、骨关节炎、强直性脊柱炎和系统性硬化症。结果显示间充质基质细胞治疗可改善骨关节炎患者疼痛视觉模拟量表评分,脂肪来源间充质基质细胞还改善WOMAC疼痛、功能和总分;安全性评估表明间充质基质细胞治疗未增加不良事件发生率。
要点
- 骨髓、脐带和脂肪来源间充质基质细胞均改善骨关节炎患者疼痛视觉模拟量表评分。
- 脂肪来源间充质基质细胞改善骨关节炎WOMAC疼痛、功能和总分。
- 安全性评估显示间充质基质细胞治疗未增加不良事件发生率。
核心结论
- 间充质基质细胞有潜力减轻炎症性关节炎患者关节疼痛并改善关节功能。
- 间充质基质细胞治疗似乎相对安全,可被视为炎症性关节炎的一种可行替代治疗选择。
研究设计与样本
- 两位研究者对中英文数据库从建库至2023年7月进行了全面检索,随后进行文献筛选和数据提取,使用RevMan 5.4软件进行统计分析。
- 最终纳入36项相关随机对照试验,共2076例参与者,涵盖类风湿关节炎、骨关节炎、强直性脊柱炎和系统性硬化症4种炎症性关节炎。
主要发现
- 骨关节炎患者疼痛视觉模拟量表评分:骨髓来源间充质基质细胞SMD=-0.95(95%CI:-1.55至-0.36,P=0.002);脐带来源SMD=-2.03(95%CI:-2.99至-1.07,P<0.0001);脂肪组织来源SMD=-1.26(95%CI:-1.99至-0.52,P=0.0009)。
- 脂肪组织来源间充质基质细胞改善骨关节炎WOMAC疼痛(P=0.0001)、WOMAC身体功能(P=0.001)和WOMAC总分(P=0.0003)。
- 对于类风湿关节炎、强直性脊柱炎和系统性硬化症,本系统评价提示间充质基质细胞对这些炎症性关节炎病症具有潜在治疗作用。
- 安全性评估表明间充质基质细胞治疗未增加不良事件发生率。
临床怎么用
- 原文结论认为间充质基质细胞有潜力减轻炎症性关节炎患者关节疼痛并改善关节功能,且似乎相对安全,可被视为炎症性关节炎的一种可行替代治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aims to assess the effectiveness and safety of mesenchymal stem cell (MSC) transplantation in the treatment of inflammatory arthritis. METHODS: Two researchers conducted a comprehensive search of Chinese and English databases from their inception until July 2023. The literature screening and data extraction were then performed. Statistical analysis was carried out using RevMan 5.4 software. RESULTS: A total of 36 relevant RCTs, involving 2,076 participants, were ultimately included in this study. These RCTs encompassed four types of inflammatory arthritis, namely rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and systemic sclerosis (SSc). The results demonstrated that MSC therapy exhibited improvements in the Visual Analog Scale (VAS) for pain in OA patients (bone marrow: SMD=-0.95, 95 % CI: -1.55 to -0.36, P = 0.002; umbilical cord: SMD=-2.03, 95 % CI: -2.99 to -1.07, P < 0.0001; adipose tissue: SMD=-1.26, 95 % CI: -1.99 to -0.52, P = 0.0009). Specifically, MSCs sourced from adipose tissue showed enhancements in Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain (P = 0.0001), WOMAC physical function (P = 0.001), and total WOMAC scores (P = 0.0003). As for MSC therapy in RA, AS, and SSc, the current systematic review suggests a potential therapeutic effect of MSCs on these inflammatory arthritic conditions. Safety assessments indicated that MSC therapy did not increase the incidence of adverse events. CONCLUSION: MSCs have the potential to alleviate joint pain and improve joint function in patients with inflammatory arthritis. Moreover, MSC therapy appears to be relatively safe and could be considered as a viable alternative treatment option for inflammatory arthritis.
引用
- Zeng L, Yang K, Yu G, et al. Efficacy and safety of culture-expanded mesenchymal stromal cell therapy in the treatment of 4 types of inflammatory arthritis: A systematic review and meta-analysis of 36 randomized controlled trials. Semin Arthritis Rheum. 2024. PMID: 38970896. doi:10.1016/j.semarthrit.2024.152498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。